大容量分子药物原料药CDMO市场－全球产业规模、份额、趋势、机会与预测：按服务、来源、最终用户、地区和竞争对手划分，2021-2031年

全球大容量药物原料药成分的合约开发和生产 (CDMO) 市场预计将从 2025 年的 128.5 亿美元增长到 2031 年的 222.8 亿美元，复合年增长率为 9.61%。

该行业的公司为单株抗体和重组蛋白等生物原料药的研发和商业化生产提供关键服务。生物製药供应链日益复杂，以及建立内部细胞培养设施所需的大量资金，迫使企业依赖拥有专业技术和营运能力的外部合作伙伴，推动了该产业的成长。

由于生物製药公司日益重视核心研发活动而非生产基础设施投资，市场前景依然乐观。欧洲製药工业协会联合会（EFPIA）预测，到2024年，肿瘤研究将占所有临床试验的约29%，凸显了对专业生物製药生产能力的强劲需求，以支持这项创新研发管线。然而，不断变化的监管环境给该领域的扩张带来了重大障碍，因为表征复杂大分子的全球标准各不相同，需要进行成本高昂的营运调整才能合规，这可能会延迟市场准入。

市场驱动因素

全球对生物製药和生物相似药的需求不断增长，成为市场成长的主要催化剂，促使製药研发公司儘早锁定大规模生产能力。随着单株抗体等高剂量疗法的商业性需求增加，创新者必须确保充足的产能，以最大限度地降低供应链风险，并确保患者能够持续获得治疗。近期的几项重大合约也印证了这种确保专业生产线的压力。三星生物製剂在2024年7月提交的监管文件中披露，该公司已与一家美国製药公司签订了一份价值约10.6亿美元的合同，这表明当前外包需求规模巨大。

同时，生物製药公司正策略性地转向资产精简模式和成本效益，以减少内部基础设施的资本支出。开发大规模生物反应器产能所带来的巨大财务负担和维护成本，促使企业越来越依赖外部合作伙伴，而这些合作伙伴也积极扩大营运规模，以满足多元化的产品线需求。富士软片迪奥辛斯生技公司（ Fujifilm Diosynth Biotechnologies）在2024年4月的新闻稿中宣布，将追加12亿美元投资，用于扩建其位于北卡罗来纳州的大型细胞培养设施，以直接应对产能需求。此次整合将使市场领导能够在支持产业创新的同时实现财务繁荣。据龙沙（Lonza）称，其2024年上半年的销售额达到31亿瑞士法郎，显示这家成熟的契约製造拥有可持续的收入来源。

市场挑战

全球聚合物类药物原料药机构（CDMO）市场的成长受到不断变化的监管环境以及适应不同全球标准的必要性的显着阻碍。由于聚合物类生物製药的结构非常复杂，不同司法管辖区的监管机构通常会要求进行各自独特的表征测试和生产控制。这种缺乏统一性迫使CDMO公司实施冗余的测试通讯协定，并为每个市场维护不同的品管体系，从而显着增加了营运成本，并限制了生产流程的全球标准化。因此，工厂产能下降，原本用于产能扩张的资金也被挪用。

监管瓶颈严重阻碍因素了产业成长，尤其是在大量治疗药物需要研发支援的情况下。根据美国药品製造商协会（PhRMA）预测，到2024年，全球将有超过8,000种药物处于临床研发阶段。如此庞大的研发管线迫使合约研发生产力机构（CDMO）加速生产进度，而因应分散的合规要求又会延缓这些产品的上市。因此，跨国快速扩张业务的困难限制了CDMO的获利能力，并减缓了整个产业的成长动能。

市场趋势

抗体药物复合体（ADC）产能的扩张正在从根本上改变这一领域。合约研发生产机构（CDMO）正投入大量资金以满足市场对这些复杂高效疗法的激增需求。 ADC的生产需要高度专业化的生物安全防护设施和偶联技术的专业知识，这迫使製药研发公司将这些技术任务外包给拥有成熟生物偶联设施的合作伙伴。对专业技术的强劲需求也反映在主要产业参与者的财务表现上。根据无锡西得生物科技有限公司于2025年3月发布的《2024财年财务报告》，该公司营收年增90.8%至40.5亿元人民币，主要得益于ADC及各类生物偶联物相关客户计划的显着增长。

同时，人工智慧数位双胞胎在製程开发的应用，正以前所未有的效率和预测控制能力，彻底改变医药原料药的生产方式。生物製药公司正日益采用这些数位化工具来模拟实验条件、优化细胞培养参数，并显着缩短从实验室到商业化生产所需的时间。这种向数据驱动型製造的转变正以惊人的速度发展。根据Benchling发布的2024年11月《生物製药技术趋势报告》，55%已应用人工智慧的机构正将该技术专门用于製程开发功能，例如细胞株开发数位双胞胎建模，以加速其营运流程。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：大型药品原料药和原料药的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按服务类型（契约製造、合约开发）
  • 依来源（哺乳动物来源、微生物来源、其他）
  • 依最终用户（生技公司、合约研究机构等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美大规模分子药物原料药与原料药市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲大规模分子药物原料药的市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区大型分子药物原料药（CDMO）的市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲大规模分子药物原料药和合约研发生产机构的市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲大规模分子药物原料药和原料药生产机构的市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：大规模分子药物原料药和原料药的全球市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Eurofins Scientific（Ireland）Limited
• WuXi Biologics Co., Ltd.
• Samsung Biologics Co Ltd
• Catalent, Inc.
• Rentschler Biopharma SE
• AGC Biologics GmbH（AGC Inc. Group）
• Recipharm AB
• Siegfried Holding AG
• Boehringer Ingelheim International GmbH
• FUJIFILM Diosynth Biotechnologies USA, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Large Molecule Drug Substance CDMO Market is projected to expand from USD 12.85 Billion in 2025 to USD 22.28 Billion by 2031, registering a CAGR of 9.61%. Organizations in this sector deliver essential services for the development and commercial production of biologic bulk drug substances, such as monoclonal antibodies and recombinant proteins. This industry growth is driven by the increasing complexity of biopharmaceutical supply chains and the substantial capital required to establish internal cell culture facilities, which compels companies to rely on external partners for their specialized technical competencies and operational capacity.

The market outlook remains favorable as biopharmaceutical firms increasingly prioritize core research activities rather than investing in manufacturing infrastructure. According to 'EFPIA', in '2024', oncology-focused studies comprised nearly 29% of all clinical trials, highlighting the robust demand for specialized biologic manufacturing capabilities to sustain this innovation pipeline. However, the sector's expansion faces significant hurdles due to the evolving regulatory landscape, as adhering to divergent global standards for characterizing complex large molecules can require expensive operational adjustments and delay market entry.

Market Driver

The rising global demand for biologics and biosimilars acts as a major catalyst for market growth, prompting pharmaceutical developers to secure large-scale manufacturing slots well ahead of time. As commercial requirements for high-volume therapeutics like monoclonal antibodies increase, innovators are forced to reserve substantial capacity to minimize supply chain risks and guarantee uninterrupted patient access. This pressure to lock in specialized production lines is evident in recent major agreements; according to Samsung Biologics, July 2024, in a 'regulatory filing', the company secured a contract worth approximately $1.06 billion with a United States-based pharmaceutical company, demonstrating the massive scale of current outsourcing needs.

Simultaneously, a strategic shift toward asset-light models and cost efficiency encourages biopharmaceutical firms to reduce capital expenditures on internal infrastructure. Developing large-scale bioreactor capacity involves immense financial overhead and maintenance, leading to a reliance on external partners who continue to aggressively expand their operational footprint to accommodate diverse pipelines. According to Fujifilm Diosynth Biotechnologies, April 2024, in a 'press release', the organization announced an additional investment of $1.2 billion to expand its large-scale cell culture facility in North Carolina, directly addressing these capacity needs. This consolidation allows market leaders to thrive financially while supporting industry innovation; according to Lonza, in 2024, the entity reported sales of CHF 3.1 billion for the first half of the year, reflecting the sustained revenue streams for established contract manufacturers.

Market Challenge

The growth of the Global Large Molecule Drug Substance CDMO Market is significantly hindered by the evolving regulatory landscape and the necessity to comply with divergent global standards. Since large molecule biologics possess high structural complexity, regulatory agencies across different jurisdictions often mandate unique characterization studies and manufacturing controls. This lack of harmonization compels CDMOs to implement redundant testing protocols and maintain distinct quality management systems for separate markets, which drastically increases operational overhead and limits the ability to standardize production processes globally, thereby reducing facility throughput and diverting capital from capacity expansions.

This regulatory bottleneck acts as a substantial constraint on growth, particularly given the massive volume of therapeutics requiring development support. According to 'PhRMA', in '2024', there were more than 8,000 medicines in clinical development globally. This extensive pipeline places immense pressure on CDMOs to accelerate manufacturing timelines; however, the friction caused by navigating fragmented compliance requirements delays market entry for these products. Consequently, the inability to swiftly scale operations across international borders restricts the revenue potential of CDMOs and slows the overall momentum of the sector.

Market Trends

The expansion of manufacturing capabilities for Antibody-Drug Conjugates (ADCs) is fundamentally reshaping the sector as CDMOs invest heavily to meet the surging demand for these complex, high-potency therapeutics. Producing ADCs requires highly specialized containment infrastructure and expertise in conjugation technologies, compelling pharmaceutical developers to outsource these technical operations to partners with established bio-conjugation suites. This intense demand for specialized capacity is reflected in the financial performance of key industry players; according to WuXi XDC, March 2025, in the 'Annual Results for 2024', the company reported a revenue increase of 90.8% year-on-year to RMB 4.05 billion, driven primarily by a significant spike in customer projects for ADCs and broader bioconjugates.

Concurrently, the integration of artificial intelligence and digital twins in process development is transforming how drug substances are manufactured by offering unprecedented levels of efficiency and predictive control. Biopharmaceutical companies are increasingly adopting these digital tools to simulate experimental conditions, optimize cell culture parameters, and drastically reduce the time required to scale up production from the laboratory to commercial facilities. This shift towards data-driven manufacturing is gaining substantial traction; according to Benchling, November 2024, in the '2024 State of Tech in Biopharma Report', 55% of organizations that have adopted AI have implemented the technology specifically within process development functions, such as cell line development and digital twin modeling, to accelerate their operational workflows.

Key Market Players

• Eurofins Scientific (Ireland) Limited
• WuXi Biologics Co., Ltd.
• Samsung Biologics Co Ltd
• Catalent, Inc.
• Rentschler Biopharma SE
• AGC Biologics GmbH (AGC Inc. Group)
• Recipharm AB
• Siegfried Holding AG
• Boehringer Ingelheim International GmbH
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

Report Scope

In this report, the Global Large Molecule Drug Substance CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Large Molecule Drug Substance CDMO Market, By Service

• Contract Manufacturing
• Contract Development

Large Molecule Drug Substance CDMO Market, By Source

• Mammalian
• Microbial
• Others

Large Molecule Drug Substance CDMO Market, By End User

• Biotech Companies
• CRO
• Others

Large Molecule Drug Substance CDMO Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Large Molecule Drug Substance CDMO Market.

Available Customizations:

Global Large Molecule Drug Substance CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Large Molecule Drug Substance CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Contract Manufacturing, Contract Development)
  • 5.2.2. By Source (Mammalian, Microbial, Others)
  • 5.2.3. By End User (Biotech Companies, CRO, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Large Molecule Drug Substance CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Source
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Large Molecule Drug Substance CDMO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Source
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Large Molecule Drug Substance CDMO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Source
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Large Molecule Drug Substance CDMO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Source
      • 6.3.3.2.3. By End User

7. Europe Large Molecule Drug Substance CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Source
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Large Molecule Drug Substance CDMO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Source
      • 7.3.1.2.3. By End User
  • 7.3.2. France Large Molecule Drug Substance CDMO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Source
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Large Molecule Drug Substance CDMO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Source
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Large Molecule Drug Substance CDMO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Source
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Large Molecule Drug Substance CDMO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Source
      • 7.3.5.2.3. By End User

8. Asia Pacific Large Molecule Drug Substance CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Source
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Large Molecule Drug Substance CDMO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Source
      • 8.3.1.2.3. By End User
  • 8.3.2. India Large Molecule Drug Substance CDMO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Source
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Large Molecule Drug Substance CDMO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Source
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Large Molecule Drug Substance CDMO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Source
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Large Molecule Drug Substance CDMO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Source
      • 8.3.5.2.3. By End User

9. Middle East & Africa Large Molecule Drug Substance CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Source
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Large Molecule Drug Substance CDMO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Source
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Large Molecule Drug Substance CDMO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Source
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Large Molecule Drug Substance CDMO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Source
      • 9.3.3.2.3. By End User

10. South America Large Molecule Drug Substance CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Source
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Large Molecule Drug Substance CDMO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Source
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Large Molecule Drug Substance CDMO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Source
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Large Molecule Drug Substance CDMO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Source
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Large Molecule Drug Substance CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eurofins Scientific (Ireland) Limited
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. WuXi Biologics Co., Ltd.
• 15.3. Samsung Biologics Co Ltd
• 15.4. Catalent, Inc.
• 15.5. Rentschler Biopharma SE
• 15.6. AGC Biologics GmbH (AGC Inc. Group)
• 15.7. Recipharm AB
• 15.8. Siegfried Holding AG
• 15.9. Boehringer Ingelheim International GmbH
• 15.10. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer